Cargando…
Long-term persistence of transcriptionally active ‘defective’ HIV-1 proviruses: implications for persistent immune activation during antiretroviral therapy
OBJECTIVES: People with HIV-1 (PWH) on effective antiretroviral therapy (ART) continue to exhibit chronic systemic inflammation, immune activation, and persistent elevations in markers of HIV-1 infection [including HIV-DNA, cell-associated HIV-RNA (CA HIV-RNA), and antibodies to HIV-1 proteins] desp...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615727/ https://www.ncbi.nlm.nih.gov/pubmed/37555786 http://dx.doi.org/10.1097/QAD.0000000000003667 |
_version_ | 1785129270031417344 |
---|---|
author | Singh, Kanal Natarajan, Ven Dewar, Robin Rupert, Adam Badralmaa, Yuden Zhai, Tracey Winchester, Nicole Scrimieri, Francesca Smith, Mindy Davis, Ivery Lallemand, Perrine Giglietti, Aude Hensien, Jack Buerkert, Thomas Goshu, Bruktawit Rehm, Catherine A. Hu, Zonghui Lane, H. Clifford Imamichi, Hiromi |
author_facet | Singh, Kanal Natarajan, Ven Dewar, Robin Rupert, Adam Badralmaa, Yuden Zhai, Tracey Winchester, Nicole Scrimieri, Francesca Smith, Mindy Davis, Ivery Lallemand, Perrine Giglietti, Aude Hensien, Jack Buerkert, Thomas Goshu, Bruktawit Rehm, Catherine A. Hu, Zonghui Lane, H. Clifford Imamichi, Hiromi |
author_sort | Singh, Kanal |
collection | PubMed |
description | OBJECTIVES: People with HIV-1 (PWH) on effective antiretroviral therapy (ART) continue to exhibit chronic systemic inflammation, immune activation, and persistent elevations in markers of HIV-1 infection [including HIV-DNA, cell-associated HIV-RNA (CA HIV-RNA), and antibodies to HIV-1 proteins] despite prolonged suppression of plasma HIV-RNA levels less than 50 copies/ml. Here, we investigated the hypothesis that nonreplicating but transcriptionally and translationally competent ‘defective’ HIV-1 proviruses may be one of drivers of these phenomena. DESIGN: A combined cohort of 23 viremic and virologically suppressed individuals on ART were studied. METHODS: HIV-DNA, CA HIV-RNA, western blot score (measure of anti-HIV-1 antibodies as a surrogate for viral protein expression in vivo), and key biomarkers of inflammation and coagulation (IL-6, hsCRP, TNF-alpha, tissue factor, and D-dimer) were measured in peripheral blood and analyzed using a combined cross-sectional and longitudinal approaches. Sequences of HIV-DNA and CA HIV-RNA obtained via 5′-LTR-to-3′-LTR PCR and single-genome sequencing were also analyzed. RESULTS: We observed similar long-term persistence of multiple, unique, transcriptionally active ‘defective’ HIV-1 provirus clones (average: 11 years., range: 4–20 years) and antibody responses against HIV-1 viral proteins among all ART-treated participants evaluated. A direct correlation was observed between the magnitude of HIV-1 western blot score and the levels of transcription of ‘defective’ HIV-1 proviruses (r = 0.73, P < 0.01). Additional correlations were noted between total CD8(+) T-cell counts and HIV-DNA (r = 0.52, P = 0.01) or CA HIV-RNA (r = 0.65, P < 0.01). CONCLUSION: These findings suggest a novel interplay between transcription and translation of ‘defective’ HIV-1 proviruses and the persistent immune activation seen in the setting of treated chronic HIV-1 infection. |
format | Online Article Text |
id | pubmed-10615727 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-106157272023-11-03 Long-term persistence of transcriptionally active ‘defective’ HIV-1 proviruses: implications for persistent immune activation during antiretroviral therapy Singh, Kanal Natarajan, Ven Dewar, Robin Rupert, Adam Badralmaa, Yuden Zhai, Tracey Winchester, Nicole Scrimieri, Francesca Smith, Mindy Davis, Ivery Lallemand, Perrine Giglietti, Aude Hensien, Jack Buerkert, Thomas Goshu, Bruktawit Rehm, Catherine A. Hu, Zonghui Lane, H. Clifford Imamichi, Hiromi AIDS Basic Science OBJECTIVES: People with HIV-1 (PWH) on effective antiretroviral therapy (ART) continue to exhibit chronic systemic inflammation, immune activation, and persistent elevations in markers of HIV-1 infection [including HIV-DNA, cell-associated HIV-RNA (CA HIV-RNA), and antibodies to HIV-1 proteins] despite prolonged suppression of plasma HIV-RNA levels less than 50 copies/ml. Here, we investigated the hypothesis that nonreplicating but transcriptionally and translationally competent ‘defective’ HIV-1 proviruses may be one of drivers of these phenomena. DESIGN: A combined cohort of 23 viremic and virologically suppressed individuals on ART were studied. METHODS: HIV-DNA, CA HIV-RNA, western blot score (measure of anti-HIV-1 antibodies as a surrogate for viral protein expression in vivo), and key biomarkers of inflammation and coagulation (IL-6, hsCRP, TNF-alpha, tissue factor, and D-dimer) were measured in peripheral blood and analyzed using a combined cross-sectional and longitudinal approaches. Sequences of HIV-DNA and CA HIV-RNA obtained via 5′-LTR-to-3′-LTR PCR and single-genome sequencing were also analyzed. RESULTS: We observed similar long-term persistence of multiple, unique, transcriptionally active ‘defective’ HIV-1 provirus clones (average: 11 years., range: 4–20 years) and antibody responses against HIV-1 viral proteins among all ART-treated participants evaluated. A direct correlation was observed between the magnitude of HIV-1 western blot score and the levels of transcription of ‘defective’ HIV-1 proviruses (r = 0.73, P < 0.01). Additional correlations were noted between total CD8(+) T-cell counts and HIV-DNA (r = 0.52, P = 0.01) or CA HIV-RNA (r = 0.65, P < 0.01). CONCLUSION: These findings suggest a novel interplay between transcription and translation of ‘defective’ HIV-1 proviruses and the persistent immune activation seen in the setting of treated chronic HIV-1 infection. Lippincott Williams & Wilkins 2023-11-15 2023-08-22 /pmc/articles/PMC10615727/ /pubmed/37555786 http://dx.doi.org/10.1097/QAD.0000000000003667 Text en Written work prepared by employees of the Federal Government as part of their official duties is, under the U.S. Copyright Act, a “work of the United States Government” for which copyright protection under Title 17 of the United States Code is not available. As such, copyright does not extend to the contributions of employees of the Federal Government. |
spellingShingle | Basic Science Singh, Kanal Natarajan, Ven Dewar, Robin Rupert, Adam Badralmaa, Yuden Zhai, Tracey Winchester, Nicole Scrimieri, Francesca Smith, Mindy Davis, Ivery Lallemand, Perrine Giglietti, Aude Hensien, Jack Buerkert, Thomas Goshu, Bruktawit Rehm, Catherine A. Hu, Zonghui Lane, H. Clifford Imamichi, Hiromi Long-term persistence of transcriptionally active ‘defective’ HIV-1 proviruses: implications for persistent immune activation during antiretroviral therapy |
title | Long-term persistence of transcriptionally active ‘defective’ HIV-1 proviruses: implications for persistent immune activation during antiretroviral therapy |
title_full | Long-term persistence of transcriptionally active ‘defective’ HIV-1 proviruses: implications for persistent immune activation during antiretroviral therapy |
title_fullStr | Long-term persistence of transcriptionally active ‘defective’ HIV-1 proviruses: implications for persistent immune activation during antiretroviral therapy |
title_full_unstemmed | Long-term persistence of transcriptionally active ‘defective’ HIV-1 proviruses: implications for persistent immune activation during antiretroviral therapy |
title_short | Long-term persistence of transcriptionally active ‘defective’ HIV-1 proviruses: implications for persistent immune activation during antiretroviral therapy |
title_sort | long-term persistence of transcriptionally active ‘defective’ hiv-1 proviruses: implications for persistent immune activation during antiretroviral therapy |
topic | Basic Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615727/ https://www.ncbi.nlm.nih.gov/pubmed/37555786 http://dx.doi.org/10.1097/QAD.0000000000003667 |
work_keys_str_mv | AT singhkanal longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy AT natarajanven longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy AT dewarrobin longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy AT rupertadam longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy AT badralmaayuden longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy AT zhaitracey longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy AT winchesternicole longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy AT scrimierifrancesca longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy AT smithmindy longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy AT davisivery longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy AT lallemandperrine longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy AT gigliettiaude longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy AT hensienjack longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy AT buerkertthomas longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy AT goshubruktawit longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy AT rehmcatherinea longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy AT huzonghui longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy AT lanehclifford longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy AT imamichihiromi longtermpersistenceoftranscriptionallyactivedefectivehiv1provirusesimplicationsforpersistentimmuneactivationduringantiretroviraltherapy |